Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novelos Therapeutics has said that the first patient has been enrolled in a phase III trial in lung cancer for its product NOV-002 in combination with first-line chemotherapy.
Subscribe to our email newsletter
This phase III trial will specifically study patients with advanced non-small cell lung cancer (NSCLC). It will evaluate NOV-002 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone. The aim of the trial will be improvement in median overall survival. Novelos is planning for patient enrollment to be completed in the first quarter of 2008.
Platinum-based chemotherapy regimens, such as paclitaxel and carboplatin, are standard first-line treatment for advanced NSCLC patients. However, the current treatments do not vastly improve survival rates and they are characterized by a high rate of severe toxicities.
“Based on overseas and US clinical data, NOV-002 added to the chemotherapy holds promise in the therapy of lung cancer and we are excited to be able to offer this trial to our patients,” said Dr Panos Fidias, from Massachusetts General Hospital.
Lung cancer is the leading cause of cancer death in the US. NSCLC accounts for more than 80% of lung cancer.